Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation

Journal of the American Society of Nephrology

Volumn 23, Issue 9, 2012, Pages 1588-1597

  Reischig, Tomas ^a   Hribova, Petra ^b   Jindra, Pavel ^a   Hes, Ondrej ^a   Bouda, Mirko ^a   Treska, Vladislav ^a   Viklicky, Ondrej ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; LYMPHOCYTE ANTIBODY; MESSENGER RNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; VALACICLOVIR; VALGANCICLOVIR;

ADULT; ARTICLE; ATROPHY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; FIBROGENESIS; GENE EXPRESSION; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUBULAR ATROPHY;

EID: 84865991144     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012010100     Document Type: Article

References (30)

1. Fishman JA: Infection in solid-organ transplant recipients. N Engl J Med 357: 2601-2614, 2007
2. Reischig T: Cytomegalovirus-associated renal allograft rejection: New challenges for antiviral preventive strategies. Expert Rev Anti Infect Ther 8: 903-910, 2010
3. Sagedal S, Nordal KP, Hartmann A, Sund S, Scott H, Degré M, Foss A, Leivestad T, Osnes K, Fauchald P, Rollag H: The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2: 850-856, 2002 (Pubitemid 36306840)
4. Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V: Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 87: 436-444, 2009
5. Smith JM, Corey L, Bittner R, Finn LS, Healey PJ, Davis CL, McDonald RA: Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 21: 1579-1586, 2010
6. Sagedal S, Hartmann A, Nordal KP, Osnes K, Leivestad T, Foss A, DegréM, Fauchald P, Rollag H: Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 66: 329-337, 2004 (Pubitemid 38870110)
7. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, Allen U, Humar A; Transplantation Society International CMV Consensus Group: International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89: 779-795, 2010
8. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD; Valganciclovir Solid Organ Transplant Study Group: Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4: 611-620, 2004 (Pubitemid 38523584)
9. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee IC; International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group: Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 340: 1462-1470, 1999 (Pubitemid 29220545)
10. Reischig T, Jindra P, Mares J, Cechura M, Svecová M, Hes O, Opatrný K Jr, Treska V: Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation 79: 317-324, 2005 (Pubitemid 40299538)
11. Hodson EM, Jones CA, Webster AC, Strippoli GF, Barclay PG, Kable K, Vimalachandra D, Craig JC: Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: A systematic review of randomised controlled trials. Lancet 365: 2105-2115, 2005 (Pubitemid 40826968)
12. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG: Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 143: 870-880, 2005 (Pubitemid 46202222)
13. Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, Gaudreault-Keener M, Koch MJ, Miller BW, Hardinger KL, Schnitzler MA, Brennan DC: Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 6: 2134-2143, 2006 (Pubitemid 44199547)
14. Reischig T, Jindra P, Hes O, Svecová M, Klaboch J, Treska V: Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 8: 69-77, 2008
15. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F: Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 8: 975-983, 2008 (Pubitemid 351537752)
16. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: The natural history of chronic allograft nephropathy. N Engl J Med 349: 2326-2333, 2003 (Pubitemid 37509740)
17. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD: Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 5: 2464-2472, 2005
18. Mannon RB, Matas AJ, Grande J, Leduc R, Connett J, Kasiske B, Cecka JM, Gaston RS, Cosio F, Gourishankar S, Halloran PF, Hunsicker L, Rush D; DeKAF Investigators: Inflammation in areas of tubular atrophy in kidney allograft biopsies: A potent predictor of allograft failure. Am J Transplant 10: 2066-2073, 2010
19. Stegall MD, Park WD, Larson TS, Gloor JM, Cornell LD, Sethi S, Dean PG, Prieto M, Amer H, Textor S, Schwab T, Cosio FG: The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 11: 698-707, 2011
20. Halloran PF, de Freitas DG, Einecke G, Famulski KS, Hidalgo LG, Menge LM, Reeve J, Sellares J, Sis B: An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant 10: 2223-2230, 2010
21. Pribylova-Hribova P, Kotsch K, Lodererova A, Viklicky O, Vitko S, Volk HD, Lacha J: TGF-beta1 mRNA upregulation influences chronic renal allograft dysfunction. Kidney Int 69: 1872-1879, 2006 (Pubitemid 43739218)
22. Benmarzouk-Hidalgo OJ, Cisneros JM, Cordero E, Martín-Peña A, Sanchez B, Martin-Gandul C, Gentil MA, Gomez-Bravo MA, Lage E, Perez-Romero P: Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation 91: 927-933, 2011
23. Nickel P, Bold G, Presber F, Biti D, Babel N, Kreutzer S, Pratschke J, Schönemann C, Kern F, Volk HD, Reinke P: High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Transpl Immunol 20: 238-242, 2009
24. Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M; VIPP Study Group: Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation 93: 61-68, 2012
25. Spinner ML, Saab G, Casabar E, Bowman LJ, Storch GA, Brennan DC: Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes. Transplantation 90: 412-418, 2010
26. Couzi L, Helou S, Bachelet T, Moreau K, Martin S, Morel D, Lafon ME, Boyer B, Alain S, Garrigue I, Merville P: High incidence of anticytomegalovirus drug resistance among D+R- kidney transplant recipients receiving pre-emptive therapy. Am J Transplant 12: 202-209, 2012
27. Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, Abramowicz D, Jardine AG, Voulgari AT, Ives J, Hauser IA, Peeters P: The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 10: 1228-1237, 2010
28. Lisboa LF, Preiksaitis JK, Humar A, Kumar D: Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients. Transplantation 92: 1063-1068, 2011
29. Preiksaitis JK, Brennan DC, Fishman J, Allen U: Canadian society of transplantation consensus workshop on cytomegalovirusmanagement in solid organ transplantation final report. Am J Transplant 5: 218-227, 2005 (Pubitemid 40179508)
30. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, Drachenberg CB, Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, Mannon RB, Marcus PB, Mengel M, Mihatsch MJ, Nankivell BJ, Nickeleit V, Papadimitriou JC, Platt JL, Randhawa P, Roberts I, Salinas-Madriga L, Salomon DR, Seron D, Sheaff M, Weening JJ: Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 7: 518-526, 2007 (Pubitemid 46376465)